Drug Trial Radar · NCT00105144
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
Last checked: Nov 19, 2026Latest source record: Sep 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
611
Actual
Start
Sep 2004
Primary completion
Apr 2006
Study completion Apr 2006
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Mar 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety and effectiveness of two dose levels of micafungin versus caspofungin in the treatment of proven invasive candidiasis or candidemia.
Conditions
- Candidiasis
- Candidemia
Interventions
MicafunginDrug
IV
CaspofunginDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall treatment success, based on the investigator's assessment of pre-defined clinical and mycological response at the End of intravenous (IV) TherapyTime frame: End of therapy and 6 weeks post-treatment
Locations
167 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Little Rock, Arkansas
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
San Francisco, California
Site not named
Denver, Colorado
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Bay Pines, Florida
Site not named
Miami, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Maywood, Illinois
Site not named
Beech Grove, Indiana
Site not named
Evansville, Indiana
Site not named
Des Moines, Iowa
Site not named
Iowa City, Iowa
Site not named
Kansas City, Kansas
Site not named
Wichita, Kansas
Site not named
Lexington, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
Jackson, Mississippi
Site not named
St Louis, Missouri
Site not named
Neptune City, New Jersey
Site not named
Albany, New York
Site not named
Manhasset, New York
Site not named
New Hyde Park, New York
Site not named
New York, New York
Site not named
New York, New York
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.